^
Association details:
| Biomarker: | EGFR L858R + EGFR T790M |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Ameile (aumolertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
YO25 - Aumolertinib treatment in L858R patient with brain metastases: A long-term survival Case Report
Published date:
11/28/2022
Excerpt:
A 55-year-old female patient with a history of hypertension presented in February 2016 due to headache, vertigo, and vomiting for one week. The diagnosis indicated stage ⅣB (cT2NxM1c) left lung adenocarcinoma with bilateral lung metastasis...We reported a 55-year-old female patient survived for more than 77 months. As we know, This case is the longest survival time reported patient with L858R and BMs so far. This case proved aumolertinib may be a good choice for T790M exon 21(L858R) NSCLC patients, especially with brain metastasis.
Source:
Title:
Successful administration of low-dose almonertinib in a patient with lung adenocarcinoma after osimertinib-induced interstitial lung disease: a case report and literature review
Excerpt:
A 64-year-old woman with no history of smoking or allergy was diagnosed with right lung adenocarcinoma...the genetic testing in plasma indicated that the EGFR T790M mutation was present in addition to EGFR 21 L858R mutation...the patient has successfully used almonertinib to control tumor progression for more than 13 months without recurrence of ILD.
DOI:
10.1097/CAD.0000000000001436
